JP2009102327A - パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法 - Google Patents

パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法 Download PDF

Info

Publication number
JP2009102327A
JP2009102327A JP2008303257A JP2008303257A JP2009102327A JP 2009102327 A JP2009102327 A JP 2009102327A JP 2008303257 A JP2008303257 A JP 2008303257A JP 2008303257 A JP2008303257 A JP 2008303257A JP 2009102327 A JP2009102327 A JP 2009102327A
Authority
JP
Japan
Prior art keywords
papilloma virus
producing
particle
same
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008303257A
Other languages
English (en)
Inventor
Lutz Gissmann
ギッスマン ラッツ
Jian Zhou
ゾウ ジアン
Martin Mueller
ミュラー マーティン
Jeanette Painstil
ペインスティル ジャネット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Loyola University Chicago
Original Assignee
Loyola University Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25940851&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2009102327(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE19944435907 external-priority patent/DE4435907C2/de
Priority claimed from DE1995126752 external-priority patent/DE19526752C2/de
Application filed by Loyola University Chicago filed Critical Loyola University Chicago
Publication of JP2009102327A publication Critical patent/JP2009102327A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

【課題】予防的および治療的ワクチン接種のためのワクチンとして好適な組み換え的に製造されたタンパク質並びにＶＬＰｓ、並びにこれらのタンパク質およびＶＬＰｓの製造方法を利用可能にすること。
【解決手段】ウイルス構造タンパク質Ｌ１および／またはＬ２の発現後に形成される組み換え的に製造されたパピローマウイルス様粒子であって、Ｌ１および／またはＬ２タンパク質の１個または複数個の部分が欠失しており、それによりウイルス様粒子を形成する能力が残存していることを特徴とする、上記のパピローマウイルス様粒子。
【選択図】なし

Description

Claims (1)

  1. 明細書に記載の発明。
JP2008303257A 1994-10-07 2008-11-27 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法 Withdrawn JP2009102327A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19944435907 DE4435907C2 (de) 1994-10-07 1994-10-07 Papillomavirusähnliche Partikel und deren Anwendung
DE1995126752 DE19526752C2 (de) 1995-07-21 1995-07-21 Hocheffiziente Bildung von Papillomavirusähnlichen Partikeln

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2005130613A Division JP2005270111A (ja) 1994-10-07 2005-04-27 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011220539A Division JP2012010713A (ja) 1994-10-07 2011-10-04 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法

Publications (1)

Publication Number Publication Date
JP2009102327A true JP2009102327A (ja) 2009-05-14

Family

ID=25940851

Family Applications (6)

Application Number Title Priority Date Filing Date
JP8512335A Withdrawn JPH11504801A (ja) 1994-10-07 1995-10-09 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
JP2005130613A Withdrawn JP2005270111A (ja) 1994-10-07 2005-04-27 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
JP2008303257A Withdrawn JP2009102327A (ja) 1994-10-07 2008-11-27 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
JP2011220539A Withdrawn JP2012010713A (ja) 1994-10-07 2011-10-04 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
JP2013112548A Withdrawn JP2013213034A (ja) 1994-10-07 2013-05-29 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
JP2014236222A Expired - Lifetime JP5794747B2 (ja) 1994-10-07 2014-11-21 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP8512335A Withdrawn JPH11504801A (ja) 1994-10-07 1995-10-09 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
JP2005130613A Withdrawn JP2005270111A (ja) 1994-10-07 2005-04-27 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2011220539A Withdrawn JP2012010713A (ja) 1994-10-07 2011-10-04 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
JP2013112548A Withdrawn JP2013213034A (ja) 1994-10-07 2013-05-29 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
JP2014236222A Expired - Lifetime JP5794747B2 (ja) 1994-10-07 2014-11-21 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法

Country Status (13)

Country Link
US (6) US6066324A (ja)
EP (2) EP0809700B1 (ja)
JP (6) JPH11504801A (ja)
AT (1) ATE325875T1 (ja)
AU (2) AU4270196A (ja)
CA (1) CA2202090C (ja)
DE (3) DE59511047D1 (ja)
DK (1) DK0809700T3 (ja)
ES (1) ES2264563T3 (ja)
LU (2) LU91401I2 (ja)
NL (2) NL300323I2 (ja)
PT (1) PT809700E (ja)
WO (1) WO1996011272A2 (ja)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164350A1 (en) 1992-09-03 2002-11-07 Lowy Douglas R. Chimeric papillomavirus-like particles
US8062642B1 (en) 1993-03-09 2011-11-22 University Of Rochester Production of papillomavirus capsid protein and virus-like particles
US6066324A (en) * 1994-10-07 2000-05-23 Loyola University Of Chicago Carboxyl terminal of papilloma virus L1 region is not required for formation of virus-like particles
US6599739B1 (en) 1996-07-17 2003-07-29 The United States Of America As Represented By The Department Of Health & Human Services Infectious papillomavirus pseudoviral particles
DE19631357A1 (de) * 1996-08-02 1998-02-05 Deutsches Krebsforsch Vektor zur Aktivierung des Immunsystems gegen mit Papillomviren bzw. Sequenzen davon assoziierten Zellen
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
WO1998028003A1 (en) * 1996-12-20 1998-07-02 Merck & Co., Inc. Formulations of recombinant papillomavirus vaccines
EP1000157A1 (en) * 1997-07-03 2000-05-17 University Technology Corporation Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture, and the use thereof as diagnostic, prophylactic or therapy
US7351533B2 (en) * 1997-09-05 2008-04-01 Medimmune, Inc. In vitro method for disassmbly/reassembly of papillomavirus virus-like particles (VLPs). Homogeneous VLP and cavsomere compositions produced by said methods: use thereof as vehicle for improved purification, and delivery of active agents
US6228368B1 (en) * 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
AU2003200653B2 (en) * 1997-10-06 2007-01-18 Loyola University Of Chicago Papilloma virus capsomere vaccine formulations and methods of use
CA2229955C (en) 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
US7182947B2 (en) * 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
DE19812940A1 (de) * 1998-03-24 1999-10-07 Medigene Ag Formulierung mit Papillomavirus-spezifischem Protein, seine Herstellung und Verwendung
US6926897B1 (en) * 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
GB9806666D0 (en) * 1998-03-27 1998-05-27 Stanley Margaret Antigen preparation and use
EP1105157B1 (en) * 1998-08-14 2006-11-02 Merck & Co., Inc. Protein delivery system using human papillomavirus virus-like particles
US6991795B1 (en) * 1998-08-14 2006-01-31 Merck & Co., Inc. Protein delivery system using human papillomavirus virus-like particles
AU750587B2 (en) 1998-10-16 2002-07-25 Smithkline Beecham Biologicals (Sa) Adjuvant systems and vaccines
SE514982C2 (sv) * 1999-09-30 2001-05-28 Active Biotech Ab Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning
DE19925199A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
DE19925235A1 (de) * 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
US20040146531A1 (en) * 1999-09-30 2004-07-29 Active Biotech Ab Virus-like particles devoid of HPV 16 type-specific antibody epitopes as carriers of peptides for introduction into cells
US6908613B2 (en) * 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
DE60137230D1 (de) * 2000-07-06 2009-02-12 Univ Georgetown Stabile (fixierte) formen von viralen l1 capsidproteinen, deren fusionsproteinen, und deren verwendungen
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
DE10137102A1 (de) * 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
WO2004042001A2 (en) * 2002-05-17 2004-05-21 Emory University Virus-like particles, methods of preparation, and immonogenic compositions
PT1506222E (pt) * 2002-05-17 2009-06-12 Univ Cape Town Proteínas l1 quiméricas do papilomavírus humano 16 incluindo um péptido l2, partículas semelhantes a vírus preparadas a partir daquelas e um método de preparação das partículas
US9045727B2 (en) * 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
US20080160040A1 (en) * 2004-04-15 2008-07-03 Ghim Shin-Je Plant-produced compositions for treating papillomavirus infection and related methods
US7732166B2 (en) * 2005-11-15 2010-06-08 Oncohealth Corporation Detection method for human pappilomavirus (HPV) and its application in cervical cancer
US7972776B2 (en) * 2005-11-15 2011-07-05 Oncohealth Corporation Protein chips for HPV detection
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
WO2008082719A2 (en) * 2006-08-30 2008-07-10 University Of Rochester Combined human papillomavirus vlp/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors
CN101148661B (zh) * 2006-09-18 2013-01-02 中国医学科学院基础医学研究所 人乳头瘤病毒16型外壳蛋白病毒样颗粒及其制备方法和用途
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
SI2068918T1 (sl) 2006-09-26 2012-09-28 Infectious Disease Res Inst Si - ep sestavek za cepljenje, ki vsebuje sintetiäśna pomagala
US8278056B2 (en) * 2008-06-13 2012-10-02 Oncohealth Corp. Detection of early stages and late stages HPV infection
US8968995B2 (en) * 2008-11-12 2015-03-03 Oncohealth Corp. Detection, screening, and diagnosis of HPV-associated cancers
WO2008115631A2 (en) * 2007-02-08 2008-09-25 University Of Louisville Research Foundation, Inc. Plant-produced compositions for treating papillomavirus infection and related methods
SI2137210T1 (sl) 2007-03-02 2017-01-31 Glaxosmithkline Biologicals S.A. Nov postopek in sestavki
DK2147926T3 (en) 2007-04-29 2016-11-28 Beijing Wantai Biological Pharmacy Entpr Co Ltd Truncated human papillomavirus type 18 L1 protein
BRPI0811016B1 (pt) 2007-04-29 2021-09-21 Xiamen Innovax Biotech Co., Ltd. Proteína li truncada do papiloma vírus humano tipo 16
CN101343315B (zh) * 2007-05-29 2012-06-13 厦门大学 截短的人乳头瘤病毒6型l1蛋白
US20100260792A1 (en) * 2007-10-22 2010-10-14 University Of Rochester Respiratory syncytial virus vaccine based on chimeric papillomavirus virus-like particles or capsomeres
EP2223933B1 (en) * 2007-11-23 2016-01-27 Shanghai Zerun Biotechnology Co., Ltd. Genes encoding major capsid protein l1 of human papilloma viruses
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
GB0820822D0 (en) 2008-11-13 2008-12-24 Inst Catala D Oncologia Novel product and processes
EP2427763A4 (en) 2009-05-07 2013-08-21 Oncohealth Corp IDENTIFICATION OF HIGH GRADE OR CIN2 FOR DETECTION, MONITORING AND DIAGNOSIS, AT EARLY STAGES AND ADVANCED STAGES, OF HUMAN PAPILLOMAVIRUS (HPV) AND HPV ASSOCIATED CANCERS
PT2437753T (pt) 2009-06-05 2016-11-23 Infectious Disease Res Inst Adjuvantes lipídicos de glucopiranosilo sintéticos e composições de vacina contendo os mesmos
WO2011084598A1 (en) 2010-01-08 2011-07-14 Oncohealth Corporation High throughput cell-based hpv immunoassays for diagnosis and screening of hpv-associated cancers
MX350795B (es) 2011-04-08 2017-09-19 Inmune Design Corp Composiciones inmunogenicas y metodos para utilizar las composiciones para inducir respuestas inmunes humorales y celulares.
JP2014523878A (ja) * 2011-06-14 2014-09-18 グローブイミューン，インコーポレイテッド Ｄ型肝炎ウイルス感染の治療又は予防のための酵母ベースの組成物及び方法
RU2610174C2 (ru) 2011-06-24 2017-02-08 Мерк Шарп И Доум Корп. Вакцинные составы против вируса папилломы человека (hpv), содержащие алюминиевый адъювант, и способы их получения
ES2558168T3 (es) 2011-09-08 2016-02-02 Uniqure Ip B.V. Eliminación de virus contaminantes en preparaciones AVV
ES2729967T3 (es) 2012-02-07 2019-11-07 Infectious Disease Res Inst Formulaciones de adyuvante mejoradas que comprenden agonistas de TLR4 y métodos para usar las mismas
WO2013139744A1 (en) 2012-03-18 2013-09-26 Glaxosmithkline Biologicals S.A. Method of vaccination against human papillomavirus
PT2850431T (pt) 2012-05-16 2018-07-23 Immune Design Corp Vacinas para hsv-2
JP6426706B2 (ja) 2013-04-18 2018-11-21 イミューン デザイン コーポレイション がん処置で使用するためのｇｌａ単剤療法
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
CN104231060B (zh) * 2013-06-05 2018-05-15 厦门大学 人乳头瘤病毒l1l2衣壳蛋白相互作用位点及其应用
JP6741580B2 (ja) 2013-12-31 2020-08-19 インフェクシャス ディズィーズ リサーチ インスティチュート 単一バイアルのワクチン製剤
WO2017200852A1 (en) 2016-05-16 2017-11-23 Infectious Disease Research Institute Formulation containing tlr agonist and methods of use
MX2018013640A (es) 2016-05-16 2019-08-01 Infectious Disease Res Inst Liposomas pegiladas y metodos de uso.
MX2021010105A (es) 2016-06-01 2022-06-16 Infectious Disease Res Inst Particulas de nanoalumbre que contienen un agente de dimensionamiento.
CA3067224A1 (en) 2017-06-15 2018-12-20 Infectious Disease Research Institute Nanostructured lipid carriers and stable emulsions and uses thereof
JP7339942B2 (ja) 2017-09-08 2023-09-06 アクセス ツー アドバンスト ヘルス インスティチュート サポニンを含むリポソーム製剤および使用方法
CA3141577A1 (en) 2019-05-25 2020-12-03 Infectious Disease Research Institute Composition and method for spray drying an adjuvant vaccine emulsion
BR112022001070A2 (pt) 2019-07-19 2022-04-19 Sinocelltech Ltd Composição de imunogenicidade polivalente para papilomavírus humano
CN114127097A (zh) * 2019-07-19 2022-03-01 神州细胞工程有限公司 嵌合的人乳头瘤病毒56型l1蛋白
CA3147850A1 (en) * 2019-07-19 2021-01-28 Sinocelltech Ltd. Chimeric papillomavirus l1 protein
CN114127099B (zh) * 2019-07-19 2024-04-19 神州细胞工程有限公司 嵌合的人乳头瘤病毒6型l1蛋白
WO2021013063A1 (zh) * 2019-07-19 2021-01-28 神州细胞工程有限公司 嵌合的人乳头瘤病毒16型l1蛋白
BR112022015313A2 (pt) 2020-02-14 2022-09-27 Merck Sharp & Dohme Llc Vacina de hpv
AU2021337493A1 (en) 2020-09-04 2023-05-18 Access To Advanced Health Institute Co-lyophilized rna and nanostructured lipid carrier
CN114539363B (zh) * 2020-11-26 2023-12-01 中国医学科学院基础医学研究所 一种c端改造的人乳头瘤病毒11型l1蛋白及其用途
CN114539365B (zh) * 2020-11-26 2023-12-01 中国医学科学院基础医学研究所 一种改造的人乳头瘤病毒52型l1蛋白及其用途
MX2023009456A (es) 2021-02-11 2023-08-28 Glaxosmithkline Biologicals Sa Preparacion de la vacuna contra el vph.
WO2022268811A1 (en) 2021-06-21 2022-12-29 Uniqure Biopharma B.V. Improved lysis procedures
TW202313658A (zh) 2021-08-06 2023-04-01 美商默沙東有限責任公司 Hpv疫苗
TW202315602A (zh) 2021-08-19 2023-04-16 美商默沙東有限責任公司 新穎熱穩定脂質奈米粒子及其使用方法
WO2024052882A1 (en) 2022-09-09 2024-03-14 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993002184A1 (en) * 1991-07-19 1993-02-04 The University Of Queensland Papilloma virus vaccine
WO1994020137A1 (en) * 1993-03-09 1994-09-15 University Of Rochester Production of human papillomavirus capsid protein and virus-like particles
JPH10506796A (ja) * 1994-10-06 1998-07-07 ザ ガヴァメント オブ ザ ユナイテッド ステイツ オブ アメリカ、アズ レプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サーヴィスィズ パピローマウイルス様キメラ粒子

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9113809D0 (en) * 1991-06-26 1991-08-14 Cancer Res Campaign Tech Papillomavirus l2 protein
GB9207701D0 (en) 1992-04-08 1992-05-27 Cancer Res Campaign Tech Papillomavirus e7 protein
JPH07505412A (ja) * 1992-04-14 1995-06-15 ブリティッシュ　バイオテック　ファーマシューティカルズリミテッド Ｃｔｌ応答の誘導
ES2294778T3 (es) 1992-06-25 2008-04-01 Georgetown University Vacunas para el virus del papiloma.
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
US6066324A (en) * 1994-10-07 2000-05-23 Loyola University Of Chicago Carboxyl terminal of papilloma virus L1 region is not required for formation of virus-like particles
AU4727296A (en) * 1995-02-24 1996-09-11 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
US5874089A (en) * 1995-10-02 1999-02-23 Georgetown University School Of Medicine Protecting against canine oral papillomavirus (copy)
US6228368B1 (en) * 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993002184A1 (en) * 1991-07-19 1993-02-04 The University Of Queensland Papilloma virus vaccine
WO1994020137A1 (en) * 1993-03-09 1994-09-15 University Of Rochester Production of human papillomavirus capsid protein and virus-like particles
JPH10506796A (ja) * 1994-10-06 1998-07-07 ザ ガヴァメント オブ ザ ユナイテッド ステイツ オブ アメリカ、アズ レプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サーヴィスィズ パピローマウイルス様キメラ粒子

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN4006005801; Ｊ．Ｖｉｒｏｌ．，Ｖｏｌ．６８，Ｎｏ．２（１９９４．Ｆｅｂ．）ｐ．６１９-６２５ *
JPN4006005802; Ｖｉｒｏｌｏｇｙ，Ｖｏｌ．１８５，Ｎｏ．２（１９９１）ｐ．６２５-６３２ *

Also Published As

Publication number Publication date
DE59511047D1 (de) 2006-06-14
US6066324A (en) 2000-05-23
DK0809700T3 (da) 2006-09-18
US6599508B1 (en) 2003-07-29
JP5794747B2 (ja) 2015-10-14
AU760615B2 (en) 2003-05-22
CA2202090C (en) 2012-04-17
ATE325875T1 (de) 2006-06-15
JP2012010713A (ja) 2012-01-19
NL300323I2 (nl) 2010-03-01
EP0809700A1 (de) 1997-12-03
US6361778B1 (en) 2002-03-26
NL300324I1 (nl) 2008-03-03
JP2013213034A (ja) 2013-10-17
LU91401I2 (fr) 2008-02-14
AU4270196A (en) 1996-05-02
US20110015376A1 (en) 2011-01-20
PT809700E (pt) 2006-09-29
DE122007000093I1 (de) 2008-03-27
ES2264563T3 (es) 2007-01-01
US20040202679A1 (en) 2004-10-14
JPH11504801A (ja) 1999-05-11
NL300323I1 (nl) 2008-03-03
US20060153864A1 (en) 2006-07-13
JP2015037430A (ja) 2015-02-26
WO1996011272A2 (de) 1996-04-18
US7416732B2 (en) 2008-08-26
AU1010600A (en) 2000-03-16
JP2005270111A (ja) 2005-10-06
DE122007000092I1 (de) 2008-03-27
EP1728800A1 (de) 2006-12-06
CA2202090A1 (en) 1996-04-18
EP0809700B1 (de) 2006-05-10
LU91390I2 (fr) 2008-02-14
WO1996011272A3 (de) 1996-09-26

Similar Documents

Publication Publication Date Title
JP2009102327A (ja) パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
DE122011100018I1 (de) Herstellung von menschlichem Papilloma-Virus-Capsid-Protein und virusahnlichen Teilchen.
DE69535018D1 (de) Papillomavirus vakzine
DE59611189D1 (de) Vp-antigene des jc-virus
EP1105157A4 (en) PROTEIN ADMINISTRATION SYSTEM USING PARTICLES LIKE THE HUMAN PAPILLOMAVIRUS.
DK0750669T3 (da) Modificeret papillomavirus-L2-protein og VLP'er dannet derudfra
CA2295316A1 (en) Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture, and the use thereof as diagnostic, prophylactic or therapy

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110406

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110705

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110708

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110805

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110810

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110905

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111004

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111021

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111222

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130129

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20130527